Skip to main content

Forbion Capital Fund IV Cooperatief U.A.'s Form 4 filing

NewAmsterdam Pharma Co N.V.NAMS · filed Jan 2, 2025

Accession no.
0000950170-25-000445
Filed
Jan 2, 2025, 4:15 PM ET
Trade date
Dec 30, 2024
Filing delay
3 days
Rule 10b5-1 plan
Checked

This filing lists 1 non-derivative transaction. Open-market sales total $762.2K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Forbion Capital Fund IV Cooperatief U.A.CIK 000182374710% Owner
Forbion Growth Opportunities Fund I Cooperatief U.A.CIK 000191104710% Owner
Forbion Growth Management B.V.CIK 000191831810% Owner
Forbion IV Management B.V.CIK 000200538410% Owner
ForGrowth NAP B.V.CIK 000200540710% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 30, 2024Ordinary SharesSSaleDisposed−29,846$25.54F2,F3−$762,174.3210,656,172Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents 13,108 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 16,738 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.30 to $26.10.

Referenced by the price of 1 transaction in Table I.

F3

(Continued from footnote 2) The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,656,172 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,003,999 are held by PoolCo and are allocated to ForGrowth, of which 4,027,712 shares are beneficially owned by Forbion Growth I and 5,976,287 shares are beneficially owned by Forbion IV.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)